Premium
Taxane‐Grafted Metal‐Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel‐Functionalized Titanate Nanotubes on Prostate Tumors
Author(s) -
Loiseau Alexis,
Boudon Julien,
Mirjolet Céline,
Créhange Gilles,
Millot Nadine
Publication year - 2017
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201700245
Subject(s) - nanomedicine , materials science , docetaxel , nanotechnology , nanoparticle , prostate cancer , bifunctional , cancer , cancer research , chemistry , medicine , organic chemistry , catalysis
The combination of anticancer drugs and metal oxide nanoparticles is of great interest in cancer nanomedicine. Here, the development of a new nanohybrid, titanate nanotube–docetaxel (TiONts–DTX) is reported, the two parts of which are conjugated by covalent linkages. Unlike most nanoparticles currently being developed for biomedical purposes, TiONts present a needle‐shaped morphology. The surface of TiONts is linked with 3‐aminopropyl triethoxysilane and with a hetero‐bifunctional polymer (polyethylene glycol) to create well‐dispersed and biocompatible nanovectors. The prefunctionalized surface of this scaffold has valuable attachments to graft therapeutic agents (DTX in our case) as well as chelating agents (1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid) to monitor the nanohybrids. To evaluate drug efficacy, in vitro tests have demonstrated that the association between TiONts and DTX shows cytotoxic activity against a hormone‐refractory prostate cancer cell line (22Rv1) whereas TiONts without DTX do not. Finally, the first in vivo tests with intratumoral injections show that more than 70% of TiONts nanovectors are retained within the tumor for at least 7 d. Moreover, tumor growth in mice receiving TiONts–DTX is significantly slower than that in mice receiving free DTX. This nanohybrid can thus become a promising new tool in biomedicine to fight against prostate cancer.